Letter to editor regarding effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes-Reference-Cited by-同舟云学术

Letter to editor regarding effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes

Published:2022-09 Issue: Volume:191 Page:110017
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Seetharaman Rajmohan^ORCID

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference4 articles.

1. Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes;Tricò;Diabetes Res Clin Pract [Internet],2022

2. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, et al. Empaglif lozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care [Internet]. 2014 Jun 1 [cited 2022 Jul 15];37(6):1650–9. Available from: https://diabetesjournals.org/care/article/37/6/1650/29568/Empagliflozin-as-Add-On-to-Metformin-in-Patients.

3. Basu D, Huggins LA, Scerbo D, Obunike J, Mullick AE, Rothenberg PL, et al. Mechanism of Increased LDL (Low-Density Lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol [Internet]. 2018 [cited 2022 Jul 15];38(9):2207–16. Available from: https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.118.311339.

4. Norwitz NG, Feldman D, Soto-Mota A, Kalayjian T, Ludwig DS. Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for a “lean Mass Hyper-Responder” Phenotype. Curr Dev Nutr [Internet]. 2022 Jan 28 [cited 2022 Jul 15];6(1). Available from: https://academic.oup.com/cdn/article/6/1/nzab144/6446805.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Authors’ reply to the letter to the editor regarding “Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes”;Diabetes Research and Clinical Practice;2022-09